Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Varicella exposure contributes only partial immunity to zoster

Roshini Claire Anthony
05 Feb 2020

Exposure to a child with varicella may reduce zoster risk in adults, even up to 20 years post-exposure, but not render them completely immune to the condition, a study from the UK showed.

The researchers of this self-controlled case series analysis looked at data of 9,604 adults (68.6 percent female) from the UK Clinical Practice Research Datalink who were diagnosed with herpes zoster (median age at diagnosis 41.1 years) between April 1997 and July 2018 who had lived with a child who had been diagnosed with varicella (median age at diagnosis 3.8 years) during the observation period (median age at exposure 38.3 years, median observation period 14.7 years).

After adjustment for age, season, and calendar time, 2 years after exposure to a child with varicella, adult participants had a 33 percent lower risk of developing zoster than at baseline (unexposed time;** incidence ratio [IR], 0.67, 95 percent confidence interval [CI], 0.62–0.73). [BMJ 2020;doi:10.1136/bmj.l6987]

This reduced risk persisted 10–20 years following exposure to a child with varicella with a 27 percent reduced risk of developing zoster among adults compared with baseline (IR, 0.73, 95 percent CI, 0.62–0.87).

The risk of developing zoster did not differ by age at exposure to varicella be it at 2-years (IR, 0.66 and 0.72 among those aged 18–49 and 50 years, respectively) or 10–20 years post-exposure (IR, 0.75 and 0.67, respectively; pinteraction=0.65). Immunosuppression status also did not affect risk of developing zoster (IR, 0.74 and 0.94 in immunocompetent and immunosuppressed individuals, respectively), at 10–20 years post-exposure to varicella (pinteraction=0.53).

However, the reduction in zoster risk was greater in men than women, with a 41 and 18 percent reduced risk, respectively, at 10–20 years post-exposure to varicella (IR, 0.59 and 0.82, respectively; pinteraction<0.001).

Zoster risk among adults with more than one household exposure to varicella was reduced, but not more so than those with only a single exposure. However, the researchers noted that the study may have been underpowered to identify this association.

The researchers also pointed out that not all varicella cases may have been captured due to the mild, self-limiting nature of the condition. “[I]t is possible that those represented in general practice records might have more severe varicella. If this was the case, we would expect the cases to have a relatively higher viral load than the average individual with varicella … by capturing more severe varicella cases, our study might have overestimated the degree of exogenous** boosting,” they said. Another limitation was that exposure to varicella in the workplace was not accounted for.

“[This study] strongly suggests that cost-effectiveness modelling studies for routine chickenpox vaccination may need revisiting,” said study lead author Dr Harriet Forbes from the London School of Hygiene and Tropical Medicine, London, UK.

“The models currently assume adults gain complete immunity to shingles for between 2 and 20 years after exposure to a person with chickenpox, whereas this study suggests adults gain only partial immunity,” she added, noting that the results “cannot be used to justify for or against any specific chickenpox vaccination schedules.”

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.